IDAI vs CLPS vs CODA vs ACXP vs PRAX

For growth investors, Coda Octopus Group, Inc.

(CODA) is the stronger pick with 30. 7% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Coda Octopus Group, Inc. (CODA) offers the better valuation at 32. 2x trailing P/E (22. 5x forward), making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Coda Octopus Group, Inc.

(CODA) delivered a total return of +49. 7%, compared to -99. 1% for T Stamp Inc. (IDAI). Over 10 years, the gap is even starker: CODA returned +844. 4% versus ACXP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CLPS Incorporation (CLPS) is the lower-risk stock at 0.

27β versus Acurx Pharmaceuticals, Inc. 's 2. 42β — meaning ACXP is approximately 790% more volatile than CLPS relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 130% for T Stamp Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Coda Octopus Group, Inc.

(CODA) is pulling ahead at 30. 7% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc. grew EPS 69. 8% year-over-year, compared to -181. 4% for CLPS Incorporation. Over a 3-year CAGR, CODA leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -344. 1% for T Stamp Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -303. 9% for IDAI. At the gross margin level — before operating expenses — CODA leads at 66. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRAX: 63.

3% to $544. 40.

In this comparison, CLPS (14.

6% yield) pays a dividend. IDAI, CODA, ACXP, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CLPS Incorporation (CLPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

27), 14. 6% yield). Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLPS: -78. 5%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IDAI (Technology) and CLPS (Technology) and CODA (Industrials) and ACXP (Healthcare) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IDAI is a small-cap quality compounder stock; CLPS is a small-cap high-growth stock; CODA is a small-cap high-growth stock; ACXP is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock. CLPS pays a dividend while IDAI, CODA, ACXP, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.